NovoCure Ltd. (NVCR)
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026
NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with positive phase 2 PANOVA-4 results in mPDAC, ongoing KEYNOTE D58 trial in GBM, and an upcoming FDA decision for NSCLC brain metastases in Q4 2026. Q1 2026 net revenues rose 12% to $174 million, driven by Optune Gio, with full-year 2026 revenue guidance raised to $690–$710 million.
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
NVCR secures European approval for Optune Pax, expanding access to its pancreatic cancer treatment after strong late-stage trial results.
Novocure's cancer treatment fails to meet late-stage trial goal
Novocure said on Thursday that its cancer treatment for newly diagnosed brain tumors did not meet the main goal of a late-stage study.
International Markets and NovoCure (NVCR): A Deep Dive for Investors
Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know
Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer
NVCR wins early FDA nod for Optune Pax in pancreatic cancer, boosting survival in phase III and opening TTFields-driven market.
NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
NovoCure secures FDA approval for Optune Pax in first-line locally advanced pancreatic cancer, the first such approval in three decades. The company is positioned for further expansion with the phase 2 PANOVA-4 trial in 1st-line metastatic pancreatic cancer; topline data is expected in Q1 2026. Full-year 2025 revenues grew 8% year-over-year to $655.4 million, supported by 4,620 active TTFields patients globally and strong U.S. sales momentum.
